

Twice-daily cysteamine bitartrate therapy for children with cystinosis.

[Dohil R](#), [Fidler M](#), [Gangoiti JA](#), [Kaskel F](#), [Schneider JA](#), [Barshop BA](#).

Department of Pediatrics, University of California San Diego, La Jolla, CA 92103-8450, USA. rdohil@ucsd.edu

OBJECTIVE: Cystinosis causes renal and other organ failure. Regular 6-hourly cysteamine bitartrate (Cystagon; Mylan, Morgantown, West Virginia) reduces intracellular cystine and the rate of organ deterioration. A formulation of cysteamine requiring less frequent dosing may improve compliance and possibly patient outcome. **METHODS:** Enteric-release cysteamine was prepared. For a period of 1 month, patients received their regular cysteamine dose every 6 hours (stage I). The patients then underwent pharmacokinetic and pharmacodynamic studies following washout periods using single-doses of cysteamine and enteric-release cysteamine (stage II). Finally, the patients commenced regular enteric-release cysteamine therapy (stage III). Weekly trough white blood cell (WBC) cystine levels were recorded. **RESULTS:** Seven children with cystinosis (mean age, 11.8 years; range, 8-17 years) who received cysteamine and enteric-release cysteamine (mean dose, 45 and 28.8 mg/kg body weight/day, respectively) had mean WBC cystine levels of 0.7+/-0.3 and 0.41+/-0.22 nmol half-cystine/mg protein in study stages I and III, respectively. Study stage II showed that the mean time (T(max)) to reach the maximum plasma cysteamine level (C(max)) was longer for enteric-release cysteamine than for cysteamine (176 minutes vs 60 minutes; P=.001), but the mean C(max) at the same dose was similar. Mean serum gastrin levels were similar after ingestion of cysteamine and enteric-release cysteamine. **CONCLUSIONS:** Twelve-hour enteric-release cysteamine, given at approximately 60% of the previous daily dose of cysteamine, was effective in maintaining trough WBC cystine levels within a satisfactory range.

PMID: 19775699 [PubMed - in process]

[Publication Types, Grant Support](#)

Publication Types:

- [Research Support, N.I.H., Extramural](#)
- [Research Support, Non-U.S. Gov't](#)

Grant Support:

- [M01RR00827/RR/NCRR NIH HHS/United States](#)

[LinkOut - more resources](#)

Full Text Sources:

- [Elsevier Science](#)

- [MD Consult](#)
- [OhioLINK Electronic Journal Center](#)
- [Ovid Technologies, Inc.](#)
- [Swets Information Services](#)

Medical:

- [Cystinosis - Genetic Alliance](#)

supplemental Content



Related articles

- [Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.](#)

Br J Clin Pharmacol. 2003 Nov; 56(5):520-5.

[Br J Clin Pharmacol. 2003]

- [Understanding intestinal cysteamine bitartrate absorption.](#)

J Pediatr. 2006 Jun; 148(6):764-9.

[J Pediatr. 2006]

- [Improved renal function in children with cystinosis treated with cysteamine.](#)

N Engl J Med. 1993 Apr 22; 328(16):1157-62.

[N Engl J Med. 1993]

- [Review: Recent advances in the treatment of cystinosis.](#)

J Inherit Metab Dis. 1995; 18(4):387-97.

[J Inherit Metab Dis. 1995]

- [Review: Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.](#)

Mol Genet Metab. 2000 Sep-Oct; 71(1-2):100-20.

[Mol Genet Metab. 2000]

- » [See reviews...](#) | » [See all...](#)

Recent activity

[Clear](#) [Turn Off](#) [Turn On](#)

- ["Schneider JA"\[Author\]\(365\)](#) **PubMed**
- [Twice-daily cysteamine bitartrate therapy for children with cystinosis](#). Twice-daily cysteamine bitartrate therapy for children with cystinosis.

Your browsing activity is empty.

Activity recording is turned off.

[Turn recording back on](#)

» [See more...](#)